Availability and quality of illegitimate somatropin products obtained from the Internet
- 338 Downloads
Background Growth hormones are widely available on the Internet for those who want to enhance their physical performance and improve body satisfaction. Illegitimate websites market somatropin injections without medical prescription and encourage misuse. Customers potentially put their health at risk when purchasing parenteral medications online. Objective The objective of our study was to evaluate the online market of no-prescription somatropin products and to analyse and document Internet pharmacy characteristics, distribution and pharmaceutical quality. Setting Websites indexed in Google promoting somatropin for sale direct to patients. Method Websites promoting the sale of growth hormone products were identified and analysed from June to August 2014. Internet vendor sites were evaluated to identify possible patient and medication safety concerns. Website characteristics, delivery time, storage conditions, packaging and attached product information were assessed. Investigation of the somatropin content was achieved using capillary electrophoresis with UV detection and electrospray ionization mass spectrometry. Main outcome measure Accessibility and quality of somatropin injections. Results Seventeen individual Internet vendor websites distributed somatropin products directly to patients, majority (94%) did not require a valid medical prescription before dispensing the products. Majority (70%) of Internet pharmacies displayed no medical information and none (0%) of the vendors displayed any regulatory body logo. All online samples had significantly (p < 0.001) lower somatropin concentration than labelled. Conclusion Our results clearly illustrate that prescription only biologic drugs are widely available online and can be easily accessed by anyone. Unprofessional distribution and handling is likely to cause degradation and possible patient safety concerns.
KeywordsGrowth hormone Illegal medicines Internet pharmacy Medication safety Online medicines Somatropin
The present scientific contribution is dedicated to the 650th anniversary of the foundation of the University of Pécs, Hungary.
This research received no external funding.
Conflicts of interest
The authors declare no conflict of interest.
- 6.United States Pharmacopeia. Somatropin for injection. In United States Pharmacopeia 37, National Formulary 32. Rockville: United States Pharmacopeial Convention Inc.; 2014. p. 4730–2.Google Scholar
- 7.European Pharmacopoeia, 7.0-1 ed. Somatropin for injection. Supplement 535th ed.; 2005. p. 3619–21. European Directorate for Quality of Medicines and Health Care. Strasbourg, France; 2014.Google Scholar
- 8.Catai JR, Sastre Toraño J, Jongen PM, de Jong GJ, Somsen GW. Analysis of recombinant human growth hormone by capillary electrophoresis with bilayer-coated capillaries using UV and MS detection. J Chromatogr B Biomed Sci Appl. 2007;852(1–2):160–6.Google Scholar
- 11.Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf Accessed 21 Aug 2016.
- 13.IMS Institute for Healthcare Informatics. Increasing numbers of innovative new medicines and orphan drugs are expected to be launched. In: The Global Use of Medicines: Outlook through 2017. IMS Institute for Healthcare Informatics. 2017. https://www.imshealth.com/files/web/IMSH%20Institute/Reports/The_Global_Use_of_Medicines_2017/global%20use%20of%20meds%202017%20right5%20Global_Models_New_Molecular_Entities.pdf Accessed 21 Aug 2016.
- 17.Gohil K. Long-acting therapies will expand growth hormone deficiency market. Pharm Ther. 2015;40(11):772–3.Google Scholar
- 20.Jung FM. Counterfeit protein drugs: how to discover and how to prevent? Eur J Hosp Pharm Pract. 2007;13(3):61–3.Google Scholar
- 23.U.S. Food and Drug Administration. Drug database. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm Accessed 21 Aug 2016.
- 24.European Medicines Agency. Drug database. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124 Accessed 21 Aug 2016.
- 25.National Institute of Pharmacy and Nutrition. Drug database. https://www.ogyei.gov.hu/drug_database/ Accessed 21 Aug 2016.
- 30.Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics. 2009;37(3):476–86, 396.Google Scholar